Drug Plan Formulary 2Nd Ed (June 2012).Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Drug Plan Formulary 2Nd Ed (June 2012).Pdf Disclaimer: This guide is offered as an easy reference to the prescription drugs that are supported by the National Prescription Drug Plan. It is by no means intended or to be construed as a directive to physicians to prescribe any of the drugs listed in the Formulary, nor does the National Insurance Board, by making available this guide, assume any responsibility for any treatment regimen or prescription drugs physicians prescribe for their patients with reference to the Formulary. The treatment and prescription process remains the sole purview of physicians in consultation with their patients. NATIONAL PRESCRIPTION DRUG PLAN FORMULARY TABLE OF CONTENTS Foreword ................................................................................. 3 Patient Registration Eligibility.................................................. 8 Completing Registration Forms .................................................. 9 Prescription Processing .......................................................... 10 Key Abbreviations .................................................................. 13 Arthritis .............................................................................. 16 Asthma ............................................................................... 45 Benign Prostatic Hypertrophy (BPH) ..................................... 58 Breast Cancer .................................................................. 63 Diabetes ............................................................................. 69 Epilepsy .............................................................................. 92 Glaucoma ......................................................................... 103 Hypercholesterolemia (High Cholesterol) ............................ 117 Hypertension .................................................................. 124 Ischaemic Disease ....................................................... 153 Prostate Cancer ............................................................ 170 Psychiatric Illness ........................................................ 177 Sickle Cell Anemia ............................................................... 201 Thyroid Diseases ................................................................. 204 ICD 9 Diagnosis Codes For NPDP Diseases ...................... 209 2 NPDP Formulary | Health Professionals Edition Foreword This booklet is intended to be a valuable resource for healthcare professionals by providing essential information regarding the National Prescription Drug Plan (NPDP). It gives an introduction to NPDP, information on patient registration, the processing of prescriptions and a comprehensive listing of the benefits offered by the Plan. Another important purpose is to answer questions you or your patients may have regarding NPDP. National data indicate that in 2010, one in three Bahamians was suffering from a chronic disease. Such ailments are costly in terms of human suffering and the expense of treatment and care. The National Insurance Board of The Bahamas, through the NPDP, seeks to reduce the health and financial burden of chronic diseases by targeting the following non-communicable diseases: arthritis, asthma, benign prostate hypertrophy, breast cancer, diabetes, epilepsy, glaucoma, hypercholestremia, hypertension, ischaemic disease, prostate cancer, psychiatric illness, sickle cell disease and thyroid disease. One element of the NIB strategy focuses on prevention by funding well organized and well managed health promotion and wellness projects in the community. The second element of the strategy addresses the following: NPDP Formulary | Health Professionals Edition 3 • Reducing cost - by negotiating medication prices through a public tender process • Increasing access- by utilizing private and public pharmacies, and • Improving health - through increased access to medications and wellness programmes. The Formulary combines both clinical and cost effectiveness. The listing of prescription drugs contained herein was developed through wide and intense consultation with practicing physicians and pharmacists in the public and private sector, as well as thorough research into similar plans that exist in other countries. We recognize that you and your patients desire choices when it comes to selecting medication. The NPDP has taken this into consideration by making available options within most of the drug classes. We ask for your assistance in supporting the goal of the NPDP to provide cost-effective therapy by being mindful of cost and appropriate use in prescribing. Another area for choice allows patients to receive their prescription benefits at any participating public or private pharmacy. The drug information in this booklet covers the products and diseases in the NPDP and is not intended to serve as a comprehensive database. If you have any questions regarding information contained herein, please contact the NPDP pharmacists for further details. If you require additional copies of any NPDP form or publication, please contact the NPDP office at 356-2032, NIB Headquarters 4 NPDP Formulary | Health Professionals Edition 502-1500, toll- free 242-300-0001 or fax 356-2026. You may also visit us online at www.nibdrugplan.com or www.nib-bahamas.com. NPDP Formulary | Health Professionals Edition 5 The National Insurance Board is grateful for your interest and support. We appreciate feedback and suggestions as to how this guide or any aspect of our services may be improved or expanded to serve you and your patients in a more efficient manner. Thank you and we look forward to providing exceptional service to you and your patients. Director The National Insurance Board 6 NPDP Formulary | Health Professionals Edition Formulary Committee Eugene Gray, MD, Chairman Kevin Bowe, MD Brenna Turnquest, Pharm. D Laura Pratt-Charlton, RPh Vivienne Lockhart, RPh Ilsa Grant-Taylor, MD Marcia Bassett, MD Specialist Review Sub-Committee Timothy Barrett, MD Conville Brown, MD Patrick Cargill, MD Dionne Dames, MD John Lunn, MD Kevin Moss, MD Vincent Nwosa, MD K.J.A. Rodgers, MD Adrian Sawyer, MD Dean Tsertopoulos, MD Geoffrey Sweeting, MD Theodore Turnquest, MD NPDP Formulary | Health Professionals Edition 7 Introducing The National Prescription Drug Plan In order to reduce the overall health expenditure burden, the National Insurance Board has devised the National Prescription Drug Plan as one of the benefits offered to its subscribers. It is hoped that by providing high quality, cost- effective medications and increased access, we can minimize the impact of chronic diseases in the Bahamas. Patient Registration Eligibility The National Prescription Drug Plan (NPDP) covers patients in the following categories: • NIB Pensioners receiving: o Retirement Benefit or Grant o Old-Age Non Contributory Pension o Survivors Benefit/Assistance (age 60 & over) o Disablement Benefit assessed at 100% • NIB Invalids receiving: o Invalidity Benefit o Invalidity Assistance • Bahamian citizens age 65 and over • Children o under 18 years o under 25 years (if full-time students) • Indigent persons • Government employees/Civil Servants • Women receiving ante-natal and post-natal care A person falling into one of the foregoing categories and 8 NPDP Formulary | Health Professionals Edition diagnosed with a covered chronic disease is eligible for NPDP, regardless of income, financial status, health insurance, or nationality. NOTE: Patients seeking to enroll and access the benefits of NPDP should possess a valid NIB number. Completing Registration Forms To register a patient for the NPDP, a licensed physician in The Bahamas needs to complete and sign Section 2 of the Patient Registration Form (DP-1). The ICD-9 code needs to be included in the diagnosis. Special Terms Regarding Diagnosis Certain diseases are considered to need specialist treatment. Diagnosis of these diseases, for the purposes of NPDP, is limited to the following certified medical specialists: • Psychiatric Illnesses: diagnosis by a psychiatrist. • Breast Cancer: diagnosis by an oncologist or surgeon. • Prostate Cancer: diagnosis by urologist or oncologist. • Glaucoma: diagnosis by an opthalmologist. Completing the Registration Process Patients must take the completed form to the NPDP office to complete the registration process and receive their ACE Rx card. Once in receipt of their card, they may fill eligible prescriptions at any participating pharmacy. NPDP Formulary | Health Professionals Edition 9 Prescription Processing Pharmacies must be registered with the NPDP to be eligible to process prescriptions for members. Patients should present their eligible prescription along with their ACE Rx card. To begin processing a NPDP prescription, the pharmacist needs to swipe the ACE Rx card through the card reader and enter the prescription information into the EPOS System. This will submit the information for processing, which will verify the eligibility of the patient and prescription. Within five (5) seconds the claim will be processed, and an approval or denial will be returned through the EPOS System. If approved, the pharmacist should then finish filling the prescription, using formulary medications purchased through the approved distributors. The authorization code returned by the Processing Centre verifies the claim has been submitted to NPDP for processing and will be paid on the next weekly pay date. If denied, a rejection message will appear. If there are any questions regarding the denial, you may contact the NPDP office for clarification.
Recommended publications
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • MORPHIC HOLDING, INC. (Name of Issuer)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 61775R 10 5 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 23, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Cusip No. G8807B106 13 D/A2 Page 2 of 7
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 31, 2016 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Corporate Governance
    65 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 66 Our Board 68 Our Corporate Executive Team 71 Leadership and effectiveness 72 Nominations Committee report 77 Accountability 79 Audit & Risk Committee report 79 Relations with stakeholders 89 Engagement activities 89 Science Committee report 91 Corporate Responsibility Committee report 92 Directors’ report 94 66 GSK Annual Report 2018 Chairman’s Governance statement “Our purpose and values have always been a source of great pride for the Board and our employees. It is a powerful force in attracting and retaining talented people who, as individuals, want to be part of a company that contributes meaningfully to society.” Dear Shareholder The Reforms came into effect on 1 January 2019 and seek to drive a I am pleased to present our Corporate Governance report for 2018. number of changes to companies’ underlying corporate governance processes. As a result, the Board has reviewed our existing practices Our governance structure operates from the Board across the Group to identify where they are in line with the Reforms and implemented and we believe it underpins our ability to deliver our strategy and enhancements where appropriate. We will report against the create long-term value and benefit for our shareholders and Reforms in next year’s Annual Report to allow time to embed these stakeholders. new practices in our corporate governance framework and to monitor I can confirm that throughout 2018 the company complied with their operation and effectiveness. the requirements of the Financial Reporting Council’s (FRC) UK However, I wish to highlight in this Report some of the more Corporate Governance Code (current Code) except that Dr Vivienne significant implementation steps which may be of interest to our Cox was unable to attend the company’s 2018 AGM.
    [Show full text]
  • United States Securities and Exchange Commission
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6*) THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 17, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Press Release
    PRESS RELEASE Issued: Tuesday 20 September 2016, London UK – LSE Announcement Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO, when he retires on 31March 2017. Emma will join the GSK Board of Directors from 1 January 2017. Emma is currently CEO of GSK Consumer Healthcare, one of the world’s largest consumer health companies, established in 2015 following completion of GSK’s three-part transaction with Novartis. Prior to this, Emma was President of GSK Consumer Healthcare and has been a member of GSK’s Corporate Executive Team since 2011. Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. Philip Hampton, GSK Chairman, said: “I am very pleased to announce Emma’s appointment, after what has been a very thorough and rigorous global selection process carried out by the GSK Board of Directors. Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare. Under Andrew’s leadership, GSK has successfully developed into a company with market-leading positions in pharmaceuticals, vaccines and consumer healthcare. These provide excellent platforms for sustainable, long-term growth, and we are confident Emma will successfully build on these strengths.” Emma Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO.
    [Show full text]
  • Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30Pm
    Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30pm Notice of Availability Electronic AGM The 2020 Annual Report and 2021 Notice of Annual General Meeting are now The AGM will be broadcast live for you to join and participate available to view and/or download in the Investors section of www.gsk.com electronically via the AGM website at https://web.lumiagm.com. Please refer to the enclosed AGM Guide or follow the instructions in the Notice of Meeting. You will need the following details to access the AGM website: Meeting ID: 140-105-232 SRN: PIN: Please note that due to COVID-19 restrictions, shareholders will unfortunately not be permitted to physically attend the meeting this year. How to vote your shares at the AGM Before completing the Proxy Form, please read the notes on appointing a proxy overleaf. You can submit your proxy instructions online (Option 1 below) or by completing and returning the Proxy Form to Equiniti (Option 2 below). In either case, your proxy instructions must be received by Equiniti by 2.30pm on Friday 30 April 2021. If you do not wish anyone other than the company or Equiniti to see the Proxy Form you may send it in an envelope to: FREEPOST RTHJ-CLLL-KBKU, Equiniti, Aspect House, Spencer Road, Lancing, BN99 8LU. No postage is required if posted within the United Kingdom. If the Proxy Form is posted outside of the United Kingdom, you should return it in an envelope, with the postage paid, to Equiniti, Aspect House, Spencer Road, Lancing, BN99 6DA.
    [Show full text]
  • GSK Delivers Q2 Sales of £7.6 Billion -2% AER, -3% CER (Pro-Forma -10% CER*) Total EPS 45.5P >100% AER; >100% CER; Adjusted EPS 19.2P -37% AER, -38% CER
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number 001-15170 GlaxoSmithKline plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F . .X. Form 40-F . Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ Issued: Wednesday, 29 July 2020, London U.K. GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*) Total EPS 45.5p >100% AER; >100% CER; Adjusted EPS 19.2p -37% AER, -38% CER Financial and product highlights ● Reported Group sales £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*; -8% CER excluding divestments/brands under review). Pharmaceuticals £4.1 billion -5% AER, -5% CER; Vaccines £1.1 billion -29% AER, -29% CER; Consumer Healthcare £2.4 billion +25% AER, +25% CER (Pro-forma -6% CER) ● H1 Reported group sales £16.7 billion 8% AER, 8% CER (Pro-forma flat CER*; +1% CER excluding divestments/brands under review) ● Sales decline in Q2 2020 reflects expected disruption from COVID-19, particularly in Vaccines as well as destocking from Q1 2020 in Pharmaceuticals and Consumer Healthcare ● Total Respiratory sales £883 million +17% AER, +16% CER.
    [Show full text]
  • GSK Annual Report 2019 01 Our Business Model Continued
    Annual Report 2019 Contents We are a science-led Strategic report Our business model 01 global healthcare company Chairman’s statement 03 CEO’s statement 04 Financial performance 06 Our long-term priorities 09 Our purpose Our culture 10 To improve the quality of human life by helping people do more, feel better, Key performance indicators 11 live longer. Industry trends 12 Stakeholder engagement 15 Our goal Pharmaceuticals 17 To become one of the world’s most innovative, best-performing and trusted Vaccines 23 healthcare companies. Consumer Healthcare 27 Trust 30 Our strategy Risk management 43 To bring differentiated, high-quality and needed healthcare products Group financial review 49 to as many people as possible, with our three global businesses, scientific Corporate Governance and technical know-how and talented people. Chairman’s Governance statement 76 Our long-term priorities Our Board 78 Our Corporate Executive Team 82 Our priorities are underpinned by our ambition to build a more performance- Responsible leadership 84 focused culture, aligned to our values and expectations. Division of responsibilities 90 Innovation Composition, succession We invest in scientific and technical excellence to develop and launch and evaluation 92 a pipeline of new products that meet the needs of patients, payers Nominations Committee report 92 and consumers. Audit, risk and internal control 96 Audit & Risk Committee report 96 Performance Science Committee report 107 We deliver growth-based performance by investing effectively in our Corporate Responsibility business, developing our people and executing competitively. Committee report 109 Trust Section 172 statement 111 We are a responsible company and commit to use our science and Directors' report 113 technology to address health needs, make our products affordable Remuneration report and available and to be a modern employer.
    [Show full text]
  • Annual Report 2017
    Annual Report Image HIV virus 2 017 GSK Annual Report 2017 GSK is a science-led global healthcare company In the Strategic report Our new CEO discusses Measuring performance 2017 performance and our and managing risk new long-term priorities See pages 05–07 See pages 18–21 How we create Innovation and Performance long-term value in each of our three businesses See pages 08–09 See pages 22–41 Industry trends How our three businesses together contribute to our Trust priority See pages 10–11 See pages 42–51 Our new long-term priorities: Financial review Innovation, Performance and Trust See pages 12–17 See pages 52–78 Cover image Cautionary statement 30 years after developing the first HIV See the inside back cover of this document medicine, our research into treatment and for the cautionary statement regarding prevention of HIV continues. We remain forward-looking statements. at the forefront of helping people living with HIV, driving innovation and working with communities all over the world. 01 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Our financial performance in 2017a £30.2bn AER +8% £6.7bn AER +51% Group turnover CER +3% New product salesb CER +44% £4.1bn AER +57% £8.6bn AER +12% Total operating profit CER +39% Adjusted operating profit CER +5% 31.4p AER +67% 111.8p AER +11% Total earnings per share CER +36% Adjusted earnings per share CER +4% £6.9bn £3.4bn £3.9bn 80p Net cash flow from Free cash flow Dividends declared 2017 dividend operating activities for 2017 per
    [Show full text]
  • Board and Committee Changes
    Board and Committee Changes Released : 06.05.2021 17:50 RNS Number : 8440X GlaxoSmithKline PLC 06 May 2021 GlaxoSmithKline plc GSK announces changes to its Board and Committees GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021. As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee. In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee. Note 1. From 6 May 2021 the Board of GSK comprises Sir Jonathan Symonds Non-Executive Chairman Emma Walmsley Chief Executive Officer Iain Mackay Chief Financial Officer Dr Hal Barron Chief Scientific Officer and President, R&D Vindi Banga Senior Independent Non-Executive Director Charles Bancroft Independent Non-Executive Director Dr Anne Beal Independent Non-Executive Director Dr Vivienne Cox Independent Non-Executive Director Lynn Elsenhans Independent Non-Executive Director Dr Jesse Goodman Independent Non-Executive Director Dr Laurie Glimcher Independent Non-Executive Director Urs Rohner Independent Non-Executive Director V A Whyte Company Secretary 6 May 2021 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 90041T 10 8 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 22, 2019 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]